NCT01162538

To Evaluate Effectiveness and Safety of Containing Raltegravir in Naive HIV NON B or B Infected Patients

The Main Objective of This Study is to Evaluate the Virologic Effectiveness at M6 of Regimen Containing Raltegravir in Treatment Naive HIV Subtype Non B or B Infected Subjects

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 60 (estimated)
• Sponsor: Centre Hospitalier Intercommunal Robert Ballanger · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Pilot open label multicentric study

Detailed description

The population VIH1 not B is not unimportant in our region of the Seine St Denis, a tendency which seems to be in increase (47 % in 2006, 67 % in 2007). Most of the studies evaluating the clinical, immunologic and virologic response to the ARV according to the viral subcategories are corresponding and show comparable results for patients infected by HIV 1 of subcategory B or non B. In spite of these reassuring results, it is necessary to evaluate the efficiency of a new ARV all the more a new class. It seems also necessary to observe attentively the profiles of resistance which will be selected at the carrier patient's of virus of subcategories not - B in failure of treatment. It will allow to determine if, because of the important polymorphisms of the viruses not - B, the evolution towards the resistance will be made differently.

Conditions

• Evaluated
• Non B Subtype
• Naive Patients

Timeline

• Start date: 2010-09-01
• Primary completion: 2011-03-01
• Completion: 2012-03-01
• First posted: 2010-07-14
• Last updated: 2010-07-14

Locations

1 site across 1 country: France